Gynesonics Announces Key Executive Appointments to Further Accelerate and Expand Adoption of the Sonata Treatment
19 mars 2024 10h00 HE
|
Gynesonics
Gynesonics announces key executive appointments to further accelerate and expand adoption of the Sonata Treatment.
Gynesonics Announces New Category 1 CPT Code for its Sonata Transcervical RF Ablation Procedure Used to Treat Uterine Fibroids
02 janv. 2024 11h13 HE
|
Gynesonics
Gynesonics Announces New Category 1 CPT Code for its Sonata Transcervical RF Ablation Procedure Used to Treat Uterine Fibroids
Gynesonics Announces $67M Financing to Expand Commercialization of Sonata® Procedure
02 nov. 2023 09h41 HE
|
Gynesonics
Gynesonics Announces $67M Financing to Expand Commercialization of Sonata® Procedure
CORRECTION – Gynesonics Announces $67M Financing to Expand Commercialization of Sonata® Procedure
01 nov. 2023 20h08 HE
|
Gynesonics
Gynesonics Announces $67M Financing to Expand Commercialization of Sonata® Procedure
Gynesonics Announces $67M Financing to Expand Commercialization of Sonata® Procedure
01 nov. 2023 16h00 HE
|
Gynesonics
Gynesonics Announces $67M Financing to Expand Commercialization of Sonata® Procedure
Gynesonics’ Incision-Free Sonata Procedure for the Treatment of Uterine Fibroids Reaches Patient Milestones in the U.S. and Globally
25 oct. 2023 16h07 HE
|
Gynesonics
Gynesonics is pleased to announce that its Sonata Procedure has been used to treat over 1,000 women in the United States in 2023
Gynesonics’ Incision-Free Sonata Procedure for the Treatment of Uterine Fibroids Reaches Patient Milestones in the U.S. and Globally
17 oct. 2023 12h00 HE
|
Gynesonics
Gynesonics' Sonata® Procedure has been used to treat over 1,000 women in the United States and approximately 6,500 women globally.
Gynesonics Names Industry Veteran Skip Baldino President and CEO, Announces $25M Financing to Expand Worldwide Commercialization
11 avr. 2023 12h00 HE
|
Gynesonics
REDWOOD CITY, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Gynesonics®, Inc. a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids,...
The Fibroid Foundation Announces Fibroid Awareness Month 2022
06 juil. 2022 15h30 HE
|
The Fibroid Foundation
WASHINGTON, July 06, 2022 (GLOBE NEWSWIRE) -- The Fibroid Foundation announces the Fibroid Awareness Month event schedule for July 2022. This Year's Fibroid Awareness Month Theme is 'Real...
ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
28 juin 2022 16h01 HE
|
ObsEva SA
-Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy- -Theramex to commercialize Yselty®; ObsEva to...